Research Funding
Year |
Total Number of Grants |
Singapore $ |
Jan-Apr 2013 |
5 (3) |
1,545,407.00 |
2012 |
9(7) |
4,682,517.00 |
2011 |
10 (10) |
6,010,395.10 |
2010 |
14 (6) |
4,330,932.00 |
2009 |
10 (5) |
3,174,625.14 |
2008 |
9 (4) |
1,849,382.27 |
2007 |
11 (3) |
2,343,813.35 |
2006 |
16 (1) |
2,495,288.00 |
2005 |
8 (2) |
872,676.74 |
2004 |
8 (1) |
563,314.00 |
2003 |
9 (1) |
988,839.00 |
2002 |
8 (3) |
977,089.31 |
2001 |
6 (0) |
395,600.00 |
2000 |
9 (0) |
920,955.00 |
1999 |
3 (0) |
97,600.00 |
1998 |
3 (0) |
177,300.00 |
1997 |
9 (1) |
2,999,673.85 |
1996 |
1 (1) |
2,212,892.07 |
Total |
148 (49) |
36,668,299.83 |
PROJECT TITLE |
PERIOD |
AMOUNT |
In Search of Novel Neuroactive Compounds Through Design and Synthesis |
NSTB/17/4/12 |
$2,212,892.07 |
1996 |
Sub-Total |
$2,212,892.07 |
GEA-NUS Pharmaceutical Processing Research Laboratory |
NSTB/17/4/21 |
$1,931,529.85 |
Design and development of transdermal therapeutic systems for peri-operative applications |
1997-2000 |
$175,866 |
Novel inhibitors of DHFR as therapeutic agents |
1997-2000 |
$36,580 |
Pharmacokinetic and pharmacodynamic drug interaction studies with warfarin in the rat |
1997-2000 |
$174,300 |
Development of immunoassays for detection of catecholamine secreting tumours |
1997-2000 |
$144,798 |
Pharmacokinetics of cefazolin in continuous ambulatory peritoneal dialysis hemodialysis (CAPD) and hemodialysis patients |
1997-2000 |
$59,000 |
Local delivery systems of anti-microbial agents in the treatment of peridontal disease |
1997-2000 |
$153,900 |
Synthesis and evaluation of oximes and related compounds as neuroactive agents |
1997-2000 |
$175,900 |
Analysis of Chinese proprietary medicine (CPM) : Undeclared Drugs & Known Active Ingredients |
1997-2000 |
$147,800 |
1997 |
Sub-Total |
$2,999,673.85 |
Synthesis & evaluation of potential antimalarial compounds |
1998-2001 |
$48,000 |
Population pharmacokinetics of aminoglycosides, digoxin & cyclosporine |
1998-2001 |
$46,600 |
Chitosan-alginate membranes |
1998-2000 |
$82,700 |
1998 |
Sub-Total |
$177,300.00 |
Application of pharmacoeconomic principles in hospital formulary selection |
1999-2001 |
$7,600 |
A pilot study on pharmacokinetics of antidepressants with lactation |
1999-2002 |
$30,000 |
Biopharmaceutics of therapeutic agents |
1999-2001 |
$60,000 |
1999 |
Sub-Total |
$97,600.00 |
Structural studies of T-cell adhesion inhibitory peptides |
2000-2002 |
$62,000 |
Polymer nanospheres for drug delivery |
2000-2003 |
$123,300 |
A study of the process of spray congealing for developing controlled release products |
2000-2002 |
$160,000 |
Development of neuroprotective agents through the intervention of nitric oxide synthase activity |
2000-2003 |
$81,910 |
Design of b-turn peptides from CD2 as therapeutic agents for autoimmune diseases |
2000-2002 |
$64,830 |
Bioactive peptides with cardiovascular properties |
2000-2002 |
$178,055 |
Pharmacokinetics and pharmacodynamics of analgesics in the control of pain |
2000-2002 |
$65,000 |
Investigations of phytochemical agents for wound healing |
2000-2001 |
$106,100 |
Analysis of Chinese herbal medicine : Profiling |
2000-2004 |
$79,760 |
2000 |
Sub-Total |
$920,955.00 |
Defining the Peptide Binding Sites on ICAM-1 Protein/(PS)10047) |
2001–2003 |
$28,000 |
Chemotherapy of Gynecological Cancers with Arsenic Compounds |
2001-2004 |
$85,000 |
Pharmacokinetics and Pharmacodynamics of Metastat, an Antiangiogenic Agent in Animals Models : Effect of Combination Chemotherapy |
2001-2004 |
$40,000 |
Formulation and Process Optimization for Single-Pot Speronization |
2001-2004 |
$50,700 |
Dietary Modulation of Drug Transport |
2001-2004 |
$124,900 |
Drug-Related Problems in Patients |
2001-2004 |
$67,000 |
2001 |
Sub-Total |
$395,600.00 |
A Pilot Study on the Pharmacokinetic Aspect of 4-Dedimethylamino Sancycline, A New Anti-Tumor Agent, in Animal Models |
2002-2005 |
$43,000 |
Antimalarial Activity of Ferrocenic Chalcones |
2002-2004 |
$68,600 |
A Study of Powder Layering for Pharmaceutical Product Development |
2002–2005 |
$102,000 |
Cellular and Molecular Modulation of Drug Transport by Common Spices in the South East Asian Diet |
BMRC Grant 01/1/21/19/142 |
$326,150 |
Preparation & evaluation of specialty pharmaceuticals excipients |
ISP Company Inc. |
$60,378.50 |
Measurement Of Health-Related Quality Of Pharmacy Life(Hrqol) In Singaporean Children With Chronic Diseases: Diabetes & Asthma |
2002–2005 |
$21,070 |
The Human Skin Barrier And Its Intercellular Lipids |
2002–2005 |
$179,950 |
Novel Phosphinegold(I) Thiolate complexes for Anti-Tumor Activity |
BMRC 01/1/21/19/119 |
$ 175,940.81 |
2002 |
Sub-Total |
$977,089.31 |
Flavonoid-related cyclin dependent pharmacy kinase inhibitors |
2003–2004 |
$75,800 |
Nano-systems to facilitate site-specific drug delivery and enhance cellular drug uptake |
2003–2006 |
$ 116,500 |
Hatchery Technology Advancements for Selected Marine Food Fish Species in Singapore : Development of Inert larval Feeds & Supplements |
AVA |
$ 376,100 |
Quality Control of Herbal Medicine and Herbal Medicinal Products |
2003–2006 |
$ 66,600 |
A Phytochemical and Neuropharmacoloical Study of Herbs that Affect the Central Nervous System |
2003–2006 |
$ 54,430 |
Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid, a New Immunosuppressant, in the Asian Renal Transplant Population in Singapore |
2003–2006 |
$ 74,500 |
Design and Synthesis of Peptides for Immuno-Modulation |
2003–2005 |
$ 67,495 |
The Synthesis and Pharmacological Study of 1,3,5-Triazines |
2003–2006 |
$ 59,490 |
Biopharmaceutics and Pharmacokinetics of Chemotherapeutic Agents and Adjuvants |
2003–2006 |
$ 97,924 |
2003 |
Sub-Total |
$988,839.00 |
High Performance Extraction and Evaluation of Botanicals for Antimicrobial Activity |
2004–2006 |
$ 96,950 |
Chemical and DNA Evaluation of Botanical Products |
2004–2006 |
$ 98,000 |
In-vitro and In-vivo Stereochemcial Metabolic Interactions Between Warfarin and Selected Complementary Medicines |
2004–2007 |
$ 61,500 |
Oxidant Properties of Chalcones |
2004–2006 |
$21,890 |
The Use of Pharmacoeconomic Approach in the Management of Osteoarthritis in Singapore |
2004–2007 |
$ 63,050 |
Design of Conjugate Peptides and peptidomimetics for Anti-inflammatory Disease |
2004–2006 |
$ 71,500 |
Functional Prediction of Novel Viral Proteins by Support Vector Machines Approach |
2004–2006 |
$97,256 |
Implementation and establishment of a joint research group between the laboratory for experimental and applied pharmacokinetic and pharmacodynamic research (LEAP2) |
SCS-PU0024 |
$53,168 |
2004 |
Sub-Total |
$563,314.00 |
Genomic, proteomic and metabonomic approaches to study the pharmacodynamic responses of chemotherapeutic agents in tumours and their metastases" |
2005-2008 |
$118,000 |
Acridines and related compounds as inhibitors of transcription factor-mediated gene expression |
2005-2008 |
$119,000 |
Design of Small Molecular Inhibitors Targeted Towards HER-2 As Therapeutic Agents for Breast Cancer |
2005-2007 |
S$ 90,000 |
Lung Cancer Treatment Using pachymic Acid from Poria Cocos |
2005-2008 |
$ 160,448 |
Development of Web-based Server for Protein-Protein Interaction Prediction from Sequence |
2005-2007 |
$38,225 |
Automated Techniques for Model Validation |
DSOCL05012 |
$80,000 |
Suspicious Behaviour Detection and Prediction System |
2005-2007 |
$31,050 |
Prostate Cancer Prevention by Pachymic Acid |
NIH 7R21CA115269-02 |
$ 235,953.74 |
2005 |
Sub-Total |
$872,676.74 |
A Comparative Study of the Burden of Illness and Impact on Functional and Pharmacoeconomic outcomes of Osteoarthritis of the Knee and Hip in Two Asian Countries : China and Korea" |
2006-2009 |
$52,000 |
Azaheterylguanidines as Synthons fpr the Preparation of Bioactive Compounds |
2006-2008 |
$84,000 |
Quantification of Surface properties to Optimize Particulate Drug Delivery System |
2006-2009 |
$132,000 |
Development of Liposome-Based Drug Combination formulations for the Treatment of Cancer |
2006-2009 |
$163,000 |
Regulation of ATP-Binding Cassette (ABC) Transporters |
2006-2008 |
$179,500 |
Medicinal Plants of Southeast Asia as Potential Sources of Lead Compounds for New Antiplatelet and Anticoagulant Drugs |
2006-2009 |
$129,300 |
Synthesis of Anti-Viral Agents with Activity Against Influenza |
2006-2008 |
$170,400 |
Simulation and Experimental Study of RAS-Mark Pathway |
2006-2008 |
$158,800 |
Design, Synthesis And Evaluation Of Heterocyclic Molecules As Potent And Selective Antagonists Towards Adensine’s Receptor Subtypes |
2006-2009 |
$179,553 |
Structural Modification of N1-diphenylmethyl-N2-nitrogguanidine for improved neuronal nitric oxide synthase selective inhibition |
2006-2009 |
$35,350 |
"Prediction of MHC-Binding Peptides of Flexible Lengths from Sequence-Derived Structural and Physicochemical Properties" |
2006-2008 |
$70,010 |
Investigations into the chemopreventive potential of small molecules: Synthesis and mode of action studies" |
2006-2009 |
$95,080 |
Establishment of alternative in vivo/in vitro models for pharmaceutical product development |
2006-2009 |
$100,135 |
Novel Biomimetic Scaffolds for the Expansion & Injectable Delivery of Human Mesenchymal Stem Cells in Cartilage Repair |
SSCC-06-005 |
$639,000 |
Understanding Structural Toxicity Relationship (STR) of Pharmaceuticals Via Characterization of Reactive Metabolite and Correlation to Hepatotoxicity |
2006-2008 |
$179,000 |
Genetic Polymorphisms of UGT1A9 Gene and Its Influence on the Pharmacokinetics of Mycophenolic Acid in the Asian Renal Transplant Population |
2006-2009 |
$128,160 |
2006 |
Sub-Total |
$2,495,288.00 |
Formulation Research on Organogels and Penetration enhancers for Dermal Drug Delivery |
2007-2010 |
$129,384 |
Nanoparticulate Drug Delivery Systems – nanocapsules |
2007-2009 |
$163,000 |
Design & Synthesis of Novel Inhibitors of Isoprenyl Cysteine Methyltransferase as Potential Anticancer Agents |
BMRC 06/1/21/19/487 |
$496,800 |
Innovative Strategy Using Selective Histone Deacetylase Inhibitor in the Management of Rheumatoid Arthritis : A Translational Study |
BMRC 06/1/21/19/441 |
$379,992 |
Development of Liposome formulations for a Protein Kinase C-specific Inhibitor in the Treatment of Cancer |
2007-2010 |
$35,000 |
Treating Drug-Resistant Cancers by Targeting Multiple Cell survival Pathways: A New Application of Liposome Technology |
2007-2010 |
$134,600 |
Polymer-lipid Derivatives as Nano-drug Carriers for Anti-Cancer, Water-Insoluble Compounds |
EDB Biomed Sci POC |
$257,060 |
Metabonomics Biomarker Study of Alzheimer’s Disease |
2007-2010 |
$179,000 |
Metabonomic fingerprinting of Neurodegenerative Diseases |
2007-2008 |
$35,000 |
Folate Receptor targeted Liposome Delivery System As the Enabling Technology to deliver a Potent, naturally-occurring Drug compound for the Treatment of Breast and |
NMRC/1109/2007 |
$358,977.35 |
Examining the abioity of Aqueous Garlic |
2007-2011 |
$175,000 |
2007 |
Sub-Total |
$2,343,813.35 |
Synthesis of fused polucyclic derivatives and thioxo analogues of 1,3,5-triazine-2, 4-dione as new inhibitors of thymidine phosphorylase for potential use in cancer chemotherapy. |
NMRC/NIG/0019/2008 |
$197,050 |
Identifying Domains of Health-related Quality of Life that are important to Multi-Ethnic Asian Patients with Diabetes Mellitus – An initial Phase in Item Bank Development. |
2008-2011 |
$179,962 |
Metabolic profiles of mesoindigo, an anti-leukemic agent: Identification of the Phase I & II metabolites in the rat, pig and human |
2008-2011 |
$120,000 |
Open Source Java-based Consensus model for Prediction of Harmful Potential of Drugs on the Liver |
2008-2010 |
$152,721 |
Investigation of new lead compounds as Adenosine receptors antagonists and their potential application in the treatment of Neurodegenerative Diseases. |
NMRC/NIG/0020/2008 |
$200,000 |
To identify & characterize oxidized protein thiols in human cells. |
2008-2011 |
$180,000 |
Application of Pharmainformatics in the clinical setting: solving drug-related problems through the innovative use of information technology. |
2008-2012 |
$179,990.70 |
Developing a Systemic Lupus Erythematosus-specific Health-Related Quality of Life Item Bank for use among Multi-Ethnic Asian Patients. |
NMRC/NIG/0039/2008 |
$159,659 |
Particulate Composite Matrix Delivery System for Enhanced Transmucosal Absorption of Photosensitzer in Oral |
NMRC/1187/2008 |
$480,000 |
2008 |
Sub-Total |
$1,849,382.27 |
Evaluation of Pharmaceutical Care & Clinical Outcome of Patients with Chronic Illnesses from Pharmacist-led Clinical Services in Singapore. |
2009–2012 |
$179,950 |
Characterization of thiol Oxidation of Keap1 in Human Cells |
2009-2012 |
$33,532.65 |
Is Sarcopenic form of Obesity associated with ageing, worse CVD risk & poorer health-related quality of life? |
2009-2010 |
$49,990 |
Evaluation of Multidisciplinary, Multifaceted Antimicrobial Stewardship Program in Singapore Hospitals |
2009-2012 |
$179,200 |
Development of new capabilities in assessing hepatotoxic potential of complementary & alternative medicine (CAM) implicated in drug-induced liver injury (DILI) |
HSA-NUS |
$119,700 |
Elucidation of the Action of Cinnamaldehydes and Shogoals on the Keap1-Nrf2-ARE Pathway |
2009-2012 |
$127,093 |
Exploring the Role of Tyrosine Kinase Tyro3 in Hepatocellular Carcinoma |
2009-2012 |
$180,000 |
Evaluation of compounds with electrophilic propensities as potential inhibitors of the thioredoxin system |
NMRC/NIG/0050/2009 |
$200,000 |
Prevalence of Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease Patients in Singapore |
2009-2012 |
$180,000 |
Pharmacoeconomic Evaluation of Treatments for Chronic Diseases |
2009-2012 |
$180,000 |
Apoptosis Signalling Mechanism in Mitochondria |
2009-2012 |
$1,200,000 |
Therapeutic Targeting of Wnt Signalling in Osteosarcoma |
2009-2010 |
$43,949.39 |
| Exploring Mesenchymal Stem Cell-Derived Conditioned Medium as Hepatoprotective Agents Against Drug-induced Liver Injuries | NMRC/NIG/1001/2009 |
$170,000 |
| Prevalence and Clinical Impact of Adverse Drug-drug Interactions in Cancer Patients | NMRC/NIG/09may028 |
$164,100 |
| In Vitro Hair Follicular Unit Reconstruction with Natural Appearance and Functions by Tissue Engineering method | NMRC/NIG/09may029 |
$167,110 |
2009 |
Sub-Total |
$3,160,675.65 |
A Benchmark Project on Early and Late Mortality from Chemotherapy |
2010-2012 |
$180,000 |
| Examination of Cardiovascular Wellness of Diabetes in Singapore | 2010-2013 |
$180,000 |
| Developing a platform for Physiological Based Pharmacokinetic and Pharmacodynamic Modelling of Innovative Therapies with Positive Emission Tomography (PET) and Computed Tomographic Scanning (CT) | CFG10P14 |
$25,000 |
| Prevalence of Vitamin D Deficiency in Pre-Dialysis Chronic Kidney Disease Patients in Singapore | NKFRC/2009/07/15 |
$40,000 |
| A study on the Role of Intercellular Transfer of Cytosolic Materials by Mesenchymal Stromal Cells for the Anti-Apoptotic Support in Hematopoietic Stem Cell Expansion and Marrow Repair | SSCC/09/021 |
$747,000 |
Jan 2010 |
Sub-Total |
$1,172,000.00 |
| Strategic Functionalizations of Carbon Nanotubes for transport, protection and delivery of drugs | FRC 2009 R2 |
$165,055 |
| Multifunctional polymeric nanoparticulate drug delivery systems for the treatment of metastatic tumors | FRC 2009 R2 |
$122,437 |
| Nanoneedle Devices for Transdermal Vaccine Delivery | MOE T2 |
$1,017,020 |
Feb 2010 |
Sub-Total |
$1,304,512.00 |
| Dissolving Microneedles for Biological Drug Delivery | Start-up grant |
$90,000 |
Mar 2010 |
Sub-Total |
$90,000.00 |
| Design, Synthesis and mechanistic studies of isoindigos as multi-targeting anti-cancer agents | FRC 2010 R1 |
$85,000 |
| Molecular profiling of fecal microRNAs for the detection of colorectal cancer | FRC 2010 R1 |
$175,000 |
Jun 2010 |
Sub-Total |
$260,000.00 |
| Metabonomic phenotyping of human nephrolithiasis | FRC 2010 R2 |
$139,433 |
| Usage of medicinal plants in South East Asia | FRC 2010 R2 |
$72,000 |
| Virtual screening of large chemical libraries to discover novel neuraminidase inhibitors against Influenza A virus | FRC 2010 R2 |
$43,157 |
Jul 2010 |
Sub-Total |
$254,590.00 |
| Preclinical studies on pharmacodynamics, disposition and systemic delivery of a novel epigenetic antitumor agent, 3-Deazaneplanocin A alone or in combination with Trichostatin A | FRC 2010 R1 |
$148,000 |
| A systematic characterization of the intrinsic drug metabolism capacity of hepatocytes differentiated from stem cells | SSCC/10/026 |
$243,783 |
Aug 2010 |
Sub-Total |
$391,783.00 |
| Quantum dot-based microfluidic device for determining the etiology of Rhinitis | SERC 102/152/0016 |
$272,875 |
Sep 2010 |
Sub-Total |
$272,875.00 |
| Development of a chromatographic method as a non-radioactive alternative assay for the mitochondrial enzyme Propionyl-CoA Carboxylase | Start-up Grant |
$90,000 |
| Investigations of Selected Medicinal Plants | Leeward Pacific PL |
$395,472 |
Nov 2010 |
Sub-Total |
$485,472.00 |
| Optimization of a Dosing Regime for Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Treatment Through Pharmacokinetic Monitoring to Achieve Better Efficacy and Safety Profile | S’pore Cancer Society |
$99,700 |
Dec 2010 |
Sub-Total |
$99,700.00 |
| Development of combined molecular modelling and machine learning methods for searching multi-target drugs and serious adverse drug reactions | NUS Bridging Grant |
$288,813 |
| Synthesis and evaluation of inhibitors of isoprenylcysteine carboxyl methyltransferase, a novel therapeutic target for oncogenesis | BMRC |
$677,890 |
| Implementing a Monitoring Tool in the Nursing Home to Aid Prescribing of Psychotropic Agents in Residents with Dementia | VISA Grant |
$20,000 |
| Design and synthesis of small molecules that target nuclear co-repressor (N-CoR) protein in acute promyelocytic leukemia | NMRC |
$97,720 |
Jan 2011 |
Sub-Total |
$1,084,423.00 |
| Towards the development of selective chemotherapeutics | Start-up Grant |
$748,900 |
| Financial Constraints in elderly to afford novel anticancer therapies – A prevalence evaluation | VISA Grant |
$18,488 |
| Cost-effectiveness of home-based medication reviews in reducing health services utilization & drug-related problems & improving health-related quality of life among multi-ethnic Singaporeans | MOH CSR |
$163,841 |
Feb 2011 |
Sub-Total |
$931,229.00 |
| Role of Secreted Wnt antagonists on osteosarcoma invasion and metastasis | FRC |
$169,600 |
| Synthetic Polymeric Derivatives as Modulators of Drug Transport Mechanisms | FRC |
$125,946 |
Apr 2011 |
Sub-Total |
$295,546.00 |
| Novel gene-enhanced peptide-PEG hybrid hydrogels for cartilage repair | MOE |
$130,000 |
| Exploration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist in Neurodegeneration Therapy – A Therapeutic Enigma | NMRC EDG |
$164,000 |
June 2011 |
Sub-Total |
$294,000.00 |
| Exploring Host Metabotype - Microbiome Interaction: A Silent Phenotype in Drug Disposition and Toxicity | BMRC |
$324,330 |
Jul 2011 |
Sub-Total |
$324,330.00 |
| Innovations in Processing of Specialties and Pharmaceuticals (iPSP) Programme – Capability Development Fund | A*Star-SERC |
$642,712 |
| Fragment-based Dual Targeted Heterocycles as Potential Anticancer Agents | FRC |
$145,800 |
| Novel Transdermal Drug Delivery Systems for Neuropathic Pain | FRC |
$177,991 |
| Effects of a Community Pharmacist-led Medication Therapy Management Service on the Elderly with Chronic Diseases in Singapore | Alice Lim Grant (External grant) |
$15,000 |
Aug 2011 |
Sub-Total |
$981,503.00 |
| Active Targeting of Tuberculosis via Novel Nanotherapeutics | NMRC |
$618,300 |
Sep 2011 |
Sub-Total |
$618,300.00 |
| A Benchmark Project on Medication Errors in Singapore | Start-up Grant |
$180,000 |
| Development of New Capabilities in assessing hepatotoxic potential of complementary and alternatives medicine (CAM) implicated in drug-induced liver injury (DILI) | HSA Grant |
$50,000(incl.IRC) |
Oct 2011 |
Sub-Total |
$230,000.00 |
| Investigation of the physiological roles of MOAP-1 in mitochondrial apoptosis signalling pathway | NMRC IRG |
$1,251,064.10 |
Dec 2011 |
Sub-Total |
$1,251,064.10 |
| Creation of Passages through Skin by Microneedles for Drug Delivery | EDB-IPP |
$100,045 |
| Human Bone Systems Biology Model | EDB-IPP |
$100,000 |
Jan 2012 |
Sub-Total |
$200,045.00 |
| Clinical predictors for chemotherapy induced nausea and vomiting among head and neck cancer Asian patients receiving cisplatin | MSD IISP Grant |
$81,600 (incl.IRC) |
| Clinical and biological determinants for Chemotherapy-Associated cognitive changes in Breast cancer patients | FRC 2012 R1 |
$126,370 |
| Improving PADEL-Descriptor, a software for calculating descriptors, by increasing number of molecular descriptors and using GPGPU programming to improve computational speed | FRC 2012 R1 |
$129,382 |
| The development of nano-probes and imaging techniques for subcellular high resolution imaging | FRC 2012 R1 |
$142,000 |
| Molecular pharmaceutics for tropical diseases | EDB IPP |
$21,400 |
| Pharmacogenetics Study of New-Onset Diabetes After Transplantation in Singapore Asian Renal Transplant Patients Receiving Calcineurin Inhibitor-Based Immunosuppression | NKF |
$40,000 |
| Assessment of the toxicological profiles and biodegradability of functionalized nanomaterials for applications in nanomedicine | MERLION Project |
$30,000 |
Apr 2012 |
Sub-Total |
$570,752.00 |
| Discovery of Biologically Active Novel Molecules for Cancer and Muscular Dystrophy Using Fragment Based Screening | NUS Start-up grant |
$862,000 |
| Dynamic Combinatorial mass spectrometric-based approach to the rapid discovery of novel substrates for JmjC histone demethylases | NUS Start-up grant |
$180,000 |
| A study of medicinal plants growing in Singapore to meet unmet medical needs | Collaboration with Leeward Pacific Pte Ltd |
$1,322,520 |
| The effectiveness of Pharmacist-involved Collaborative Care Model in the Management of Patients with Diabetes Mellitus in Singapore | HSR Grant |
$1,192,000 (incl.20% IRC) |
Sep 2012 |
Sub-Total |
$3,556,520.00 |
| Innovative strategy using stilbene analogues of resveratrol in the management of inflammatory diseases: A proof-of-concept study | NUS Start-up grant |
$180,000 |
| A comparison of Patient-reported, Economic and Clinical Outcomes between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population | FRC Grant |
$125,200 |
Oct 2012 |
Sub-Total |
$305,200.00 |
| Synthesis and mechanistic studies of novel agents for Hepatocellular Carcinoma | FRC Grant |
$50,000 |
Nov 2012 |
Sub-Total |
$50,000.00 |
| Understanding the role of MOAP-1 in normal ageing and catastrophic brain injury. (Co-PI) | MOE T2 |
$110,000 |
| Understanding the interplay between cell death pathways and HCV infection. (Co-PI) | MOE T2 |
$180,000 |
Jan 2013 |
Sub-Total |
$290,000.00 |
| Improved virtual screening method and discovery of Multitarget kinase inhibitors | FRC Grant |
$169,500 |
| Stereoselective transport of pioglitazone through blood-brain barrier in the treatment of Alzheimer’s disease | FRC Grant |
$177,101 |
| Novel Method of Fabricating Large-Area Microneedle Arrays | NRF POC |
$216,000 |
| Unravelling the chemistry of catecholic building blocks: Biomimetic approaches to new materials | A*Star PSF |
$379,680 (inc.20% IRC) |
| A fast micro-Raman system for high-resolution chemical imaging in biomedicine. (Co-PI) | A*Star PSF |
$133,200 (inc.20% IRC) |
Feb 2013 |
Sub-Total |
$1,075,481 |
| Evaluation and characterization of the anti-invasive and anti-inflammatory properties of compounds with natural origins and their novel derivatives | FRC Grant |
$179,926 |
Apr 2013 |
Sub-Total |
$179,926.00 |
Sources of funding
NUS Office of the Deputy President (Research and Technology)
A*Star - Agency for Science, Technology and Research
